본문으로 건너뛰기
← 뒤로

PD-1/PD-L1 Signaling in Non-ICI Myocarditis.

JACC. Basic to translational science 2026 p. 101539

Yousif LI, Sijtema AG, Appels Y, van den Berg PF, Aboumsallem JP, Manintveld OC, Duncker DJ, de Boer RA, Meijers WC

📝 환자 설명용 한 줄

Immune checkpoint inhibitor (ICI)-mediated myocarditis is a notorious complication of cancer treatment; however, the role of immune checkpoints in the heart during inflammation remains unknown.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Yousif LI, Sijtema AG, et al. (2026). PD-1/PD-L1 Signaling in Non-ICI Myocarditis.. JACC. Basic to translational science, 101539. https://doi.org/10.1016/j.jacbts.2026.101539
MLA Yousif LI, et al.. "PD-1/PD-L1 Signaling in Non-ICI Myocarditis.." JACC. Basic to translational science, 2026, pp. 101539.
PMID 42001325

Abstract

Immune checkpoint inhibitor (ICI)-mediated myocarditis is a notorious complication of cancer treatment; however, the role of immune checkpoints in the heart during inflammation remains unknown. We investigated myocardial expression of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) in non-ICI myocarditis. We performed a cross-species single-cell/-nucleus RNA sequencing comparative analysis, including 3 different models of myocarditis in mice and human hearts, with in vitro validation in human cells. This provided compelling evidence that PD-1/PD-L1 signaling in both murine and human non-ICI myocarditis is inherent to the myocardial inflammatory response. Specifically, cardiac endothelial cells and fibroblasts exhibited robust and sustained PD-L1 up-regulation in myocarditis, while also coinciding temporally with peak PD-1 expression on T cells, which presents an important defense mechanism. Therefore, immune checkpoints have global importance in myocarditis and may serve as a therapeutic target.